Insider Selling: Exagen (NASDAQ:XGN) CEO Sells 11,430 Shares of Stock

Exagen Inc. (NASDAQ:XGN) CEO John Aballi sold 11,430 shares of Exagen stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $3.61, for a total value of $41,262.30. Following the sale, the chief executive officer directly owned 702,997 shares in the company, valued at $2,537,819.17. The trade was a 1.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Exagen Price Performance

Shares of NASDAQ XGN traded up $0.11 during trading hours on Wednesday, reaching $3.80. The stock had a trading volume of 285,892 shares, compared to its average volume of 457,148. Exagen Inc. has a twelve month low of $2.67 and a twelve month high of $12.23. The business’s fifty day moving average is $4.80 and its two-hundred day moving average is $7.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 4.08 and a current ratio of 4.08.

Hedge Funds Weigh In On Exagen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XGN. Acadian Asset Management LLC bought a new stake in Exagen during the first quarter worth about $25,000. Geode Capital Management LLC grew its position in Exagen by 45.6% during the 2nd quarter. Geode Capital Management LLC now owns 146,483 shares of the company’s stock worth $1,023,000 after acquiring an additional 45,884 shares during the last quarter. Calamos Advisors LLC bought a new stake in Exagen during the 2nd quarter worth approximately $526,000. Citizens Financial Group Inc. RI acquired a new stake in Exagen during the 2nd quarter valued at $472,000. Finally, XTX Topco Ltd bought a new position in Exagen in the 2nd quarter valued at $133,000. 75.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on XGN shares. TD Cowen decreased their target price on shares of Exagen from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Exagen in a research note on Wednesday, January 21st. B. Riley Financial reaffirmed a “buy” rating and set a $8.00 price objective (down from $18.00) on shares of Exagen in a report on Friday, January 30th. Finally, BTIG Research dropped their target price on Exagen from $15.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Exagen has an average rating of “Moderate Buy” and an average target price of $11.43.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.